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Abstract
Hirschsprung disease (HSCR) is a congenital and heterogeneous disorder characterized by the absence of intramural
nervous plexuses along variable lengths of the hindgut. Although RET is a well-established risk factor, a recent genome-wide
association study (GWAS) of HSCR has identified NRG1 as an additional susceptibility locus. To discover additional risk loci,
we performed a GWAS of 123 sporadic HSCR patients and 432 unaffected controls using a large-scale platform with
coverage of over 1 million polymorphic markers. The result was that our study replicated the findings of RET-CSGALNACT2-
RASGEF1A genomic region (rawP= 5.69610
219 before a Bonferroni correction; corrP= 4.31610
213 after a Bonferroni
correction) and NRG1 as susceptibility loci. In addition, this study identified SLC6A20 (adjP= 2.71610
26), RORA
(adjP= 1.26610
25), and ABCC9 (adjP= 1.86610
25) as new potential susceptibility loci under adjusting the already known
loci on the RET-CSGALNACT2-RASGEF1A and NRG1 regions, although none of the SNPs in these genes passed the Bonferroni
correction. In further subgroup analysis, the RET-CSGALNACT2-RASGEF1A genomic region was observed to have different
significance levels among subgroups: short-segment (S-HSCR, corrP= 1.71610
25), long-segment (L-HSCR, corrP= 6.66610
24),
and total colonic aganglionosis (TCA, corrP.0.05). This differential pattern in the significance level suggests that other
genomic loci or mechanisms may affect the length of aganglionosis in HSCR subgroups during enteric nervous system (ENS)
development. Although functional evaluations are needed, our findings might facilitate improved understanding of the
mechanisms of HSCR pathogenesis.
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Introduction
Hirschsprung disease (HSCR, or aganglionic megacolon) is a
rare congenital disease (1 in 5000 live births) that leads to intestinal
obstruction or chronic constipation. HSCR manifests a sex-
dependent penetrance (male:female ratio of ,4:1) and involves
mostly sporadic cases; however, 5–20% are familial forms. Based
on the length of aganglionosis, patients can be further classified
into three groups as follows: (1) short-segment (S-HSCR, ,80% of
cases) with aganglionosis affecting the rectum and not extending
beyond the upper sigmoid, (2) long-segment (L-HSCR, ,15%)
with aganglionosis affecting longer tracts of the colon, and (3) total
colonic aganglionosis (TCA, ,5%) [1,2]. Genetic variations in
eight genes, including RET, have been implicated in less than 30%
of HSCR development, indicating the need to identify additional
HSCR-causing variations.
The RET proto-oncogene, encoding a tyrosine-kinase receptor,
has been identified as the major HSCR gene. In particular, a
common variant rs2435357 (also known as RET+3) within a
conserved enhancer-like sequence in intron 1 of RET showed a
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significant association with HSCR susceptibility, with different
genetic effects between male and female patients [3]. Since this
variant is located in an enhancer-like sequence, it was further
speculated that additional factors might interact with this variant
to affect RET expression. Two downstream genes that are near
RET, CSGALNACT2 and RASGEF1A, are differentially ex-
pressed between the colon and small intestine [3], although the
functions of these genes have not been adequately characterized.
Mutations in other genes (EDNRB, GDNF, NRTN, SOX10,
etc.) have also been identified as contributing to HSCR
development [1,2,4,5]. Recently, the first genome-wide association
study (GWAS) of HSCR has additionally identified neuregulin 1
(NRG1), one of the molecular regulators in the development and
maintenance of the enteric nervous system (ENS), as a suscepti-
bility locus for HSCR [6]. Follow-up studies have also evaluated
the potential effects of NRG1 on HSCR, including aberrant
NRG1 expression [7,8]; however, results from these studies suggest
that other alleles or epigenetic factors might affect NRG1
expression. Moreover, still other factors (for instance, APOB,
RELN, GAL, etc.) have been proposed that may be associated
with HSCR development [9,10].
Given that HSCR is a heterogeneous disorder, new confounders
with small-to-modest effects on HSCR development have yet to be
discovered. RET coding sequence mutations account for about
50% in familial HSCR and 15–20% in sporadic HSCR [1]. In this
study, we have performed GWAS using sporadic HSCR to
discover additional risk loci and to validate previous discoveries
using a larger number of single nucleotide polymorphism (SNP)
markers.
Subjects and Methods
Study subjects
Study subjects were collected from Samsung Medical Center,
Asan Medical Center, Severance Children’s Hospital, and Seoul
National University Children’s Hospital in Korea. The study
protocol was approved by the Institutional Review Board of each
hospital (IRB No. SMC_2010-02-028-003 of Samsung Medical
Center; 2010-0395 of Asan Medical Center; 4-2010-0436 of
Severance Children’s Hospital; 1006-129-322 of Seoul National
University Children’s Hospital), and guardians of all subjects
provided written informed consent. All subjects were of Korean
ethnicity. A total of 124 sporadic HSCR patients (102 males and
22 females) were recruited, and their biopsy specimens or surgical
materials were used to make the diagnosis of HSCR by histological
examination based on the absence of the enteric ganglia. Patients
were composed of 76 S-HSCR, 31 L-HSCR, and 17 TCA. For
the controls, 450 unaffected subjects (250 males and 200 females)
with no history of HSCR based on the questionnaire information
about concomitant disease, but without exclusion criteria for other
neurological diseases or gastroenterological diseases, were included
from Ansan cohort provided by Korea BioBank, Center for
Genome Science, National Institute of Health, Korea Centers for
Disease Control and Prevention. However, 19 subjects (1 S-HSCR
patient and 18 controls) were excluded from all analyses because
they were detected as outliers based on the principal component
analysis (PCA) and revealed as mixed-bloods.
Genome-wide genotyping
Genomic DNAs were extracted from the peripheral blood
lymphocytes of the patients and unaffected controls, using the
Wizard Genomic DNA Purification Kit (Promega, WI, USA),
according to the manufacturer’s protocol. A whole-genome
genotype scan was performed using about 200 ng of the genomic
DNAs on Illumina’s HumanOmni1-Quad BeadChip (Illumina,
San Diego, USA), according to the manufacturer’s protocol. All
samples were scanned using the Illumina iScan system (Illumina),
and the normalized bead intensity data were loaded into the
GenomeStudio software (Illumina). Considering a potential
association between rare variants and rare diseases such as
HSCR, this study included all polymorphic markers for association
analysis. For 1,140,419 markers on the chip, SNP marker quality
control (QC) was applied as follows: (1) only SNP with call rate (.
98%, 995,666 markers) in both cases and controls was included, (2)
221,556 monomorphic markers were excluded, and (3) visual
inspection of the genotype cluster image was performed for the
SNPs with deviation from Hardy-Weinberg equilibrium (HWE,
P,0.0001), and 16,850 SNPs deviating from HWE were excluded
from the analysis. The 757,260 markers that remained after QC
were ultimately used for further association analysis.
Statistics
Associations of genotype distributions were calculated by logistic
regression analysis using HelixTree software (Golden Helix,
Bozeman, MT, USA). The possible population stratification was
examined by PCA using HelixTree software. A Bonferroni
correction applied by the number of independent SNPs
(757,260), which resulted in the threshold of GWAS significance
(corrP=6.6610
28), was calculated. In order to remove the effects
of primary top signals from the known RET-CSGALNACT2-
RASGEF1A genomic region on chromosome 10q11.2 and the
effect of the first GWAS-discovered NRG1 on chromosome 8p12,
four SNPs, including rs2435357, rs1800860, and rs7078220 on
RET-CSGALNACT2-RASGEF1A region and rs16879552 on
NRG1, were adjusted as covariates. In the case of the three SNPs
on RET-CSGALNACT2-RASGEF1A region, they were likely to
make a major contribution to the strongest signal according to our
GWAS results. Therefore, P-values were defined as follows: rawP
for raw P-value before a Bonferroni correction, corrP after a
Bonferroni correction, and adjP under adjusting the known RET-
CSGALNACT2-RASGEF1A and NRG1 loci. The FaST-LMM
(Factored Spectrally Transformed Linear Mixed Models) program
was applied to correct for hidden relatedness [11]. Statistical
power of the sample size was calculated using the Power for
Genetic Association Analyses (PGA) software [12], with false
positive rate of 5%, disease prevalence of 0.02% (1 in 5000 live
births) [1], given minor allele frequencies of the most significant
allele and sample sizes of case (n = 123) and control (n = 432), and
assuming a relative risk of 1.5, resulting in the statistical
power = 58.5%. Analysis of linkage disequilibrium (LD) among
the SNPs was performed using the Haploview v4.2 software
downloaded from the Broad Institute (http://www.broadinstitute.
org/mpg/haploview) based on LD coefficients (|D’| and r2)
between all pairs of biallelic loci.
Results
Characteristics of study subjects
After excluding outliers based on the PCA (Figure S1), a total of
555 subjects (123 sporadic HSCR patients and 432 unaffected
controls) were involved in the GWAS. Although our study subjects
showed genomic control inflation factor (l) of 1.077, this inflation
factor was reduced to 1.015 after correcting for hidden relatedness
using FaST-LMM. Male:female ratio was ,4.9:1, as was expected
based on general sex differences in HSCR. Patients were classified
into groups of 75 S-HSCR (60.1% of cases; 65 male, 10 female),
31 L-HSCR (25.2% of cases; 24 male, 7 female), and 17 TCA
(13.8% of cases; 13 male, 4 female), indicating that the proportion
GWAS of Hirschsprung Disease
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of patients with L-HSCR and TCA in this study was slightly
higher than the expected prevalence of each subgroup.
Association analysis and identification of new
susceptibility locus
A quantile-quantile (Q-Q) plot for the association test with
HSCR showed a significant deviation of measures at the tail
(Figure 1A), even after excluding SNPs in the RET-CSGAL-
NACT2-RASGEF1A region on chromosome 10q11.2 (Figure S2),
indicating potentially true associations between the SNPs and
HSCR. Our GWAS confirmed two facts previously reported.
First, the strongest significant association was observed at the
RET-CSGALNACT2-RASGEF1A genomic region (Figure 1B),
with top signal at kgp4676284 (rs1864400, rawP=5.69610
219
before a Bonferroni correction; corrP=4.31610
213 after a
Bonferroni correction, Table S1). Second, NRG1 also showed
association signals (Table S2).
No other individual SNPs reached a genome-wide significance
(Bonferroni-corrected significance) level, except for five SNPs (two
intronic rs12739262 and rs35198051; three intergenic
rs12752277, rs2809867, and rs36019094; Figure 1B and Table
S3). To identify additional signals under exclusion of effects from
the RET-CSGALNACT2-RASGEF1A region and from the first
GWAS-discovered NRG1, further analysis was employed by
adjusting for four SNPs, rs2435357, rs1800860, and rs7078220 on
the RET-CSGALNACT2-RASGEF1A region (these three SNPs
were confirmed to sufficiently represent the region) and
rs16879552 on NRG1. The strongest association was detected at
SLC6A20 encoding solute carrier family 6, proline IMINO
transporter, member 20 (rs4299518, adjP=2.71610
26;
rs2159272, adjP=2.66610
25; Table 1 and Figure 2). In the
regional association of 400 kb around SLC6A20 on chromosome
3p21.3 (Figure 3A), seven SNPs of SLC6A20 showed relatively
robust association signals (minimum adjP=2.71610
26, Table S4).
LD analysis revealed that SLC6A20 SNPs showing potential
associations with HSCR were likely to not be in LD with nearby
genes (Figure 3A). In addition, RORA (minimum
adjP=1.26610
25) and ABCC9 (minimum adjP=1.86610
25),
along with relatively strong regional associations (Figure 3B and
3C), were detected as potential risk loci for HSCR (Table 1 and
Table S4).
In the further analysis under adjusting the known RET-
CSGALNACT2-RASGEF1A and NRG1 loci, other genes includ-
ing CDKAL1 (adjP=1.96610
25), ACCSL (adjP=1.13610
25), and
ASTN1 (adjP=7.63610
25) also showed potential associations
with HSCR (Table 1 and Table S5).
Analysis of HSCR subgroups
In addition to RET, two of its downstream genes, CSGAL-
NACT2 and RASGEF1A, showed similar levels of significance
regarding HSCR susceptibility and were in tight LD (Figure S3).
In our further analysis among subgroups, this RET-CSGAL-
NACT2-RASGEF1A genomic region showed different signifi-
cance levels among subgroups (corrP=1.71610
25 in S-HSCR;
corrP=6.66610
24 in L-HSCR; corrP.0.05 in TCA; Table S6 and
Figure 4).
Discussion
HSCR is a complex and heterogeneous disease. In addition, the
incidence of HSCR is much higher in males, and a higher
maternal inheritance than paternal (largely transmitted to the son)
is observed in RET coding sequence mutations, based on the
assumption of parent-of-origin effect [13]. Although mutations in
RET (in particular, a common variant rs2435357 within a
conserved enhancer-like sequence) and other genes (such as
GDNF, SOX10, and endothelin-related genes) have partially
accounted for HSCR development [3–5,14], comprehensive
genetic implications for HSCR and ENS development are still
not fully understood. Inspired by the discovery of NRG1 as an
additional susceptibility locus from GWAS of HSCR, we
performed another GWAS using a large-scale platform with
coverage of over 1 million markers to identify additional risk
factors and to investigate potential genetic effects among HSCR
subgroups. As a result, this study identified SLC6A20 and ABCC9
as potential susceptibility loci and the possible reduced effects of
the RET-CSGALNACT2-RASGEF1A genomic region according
to length of aganglionosis.
Consistent with results of the first GWAS [6], we also replicated
the finding that NRG1 on chromosome 8 might be a susceptibility
locus for HSCR (Figure 1B and Table S2). Due to the different
GWAS array platforms, only NRG1 rs16879552 in our GWAS
was matched and could be compared to that of the previous
GWAS. This study showed a nominal relevance at rs16879552
(Table S2), whereas the first GWAS revealed a higher association
signal [6]. Since this study included no hereditary HSCR cases,
Figure 1. Overview of genome-wide association results. (A) Q-Q plot. The observed P-value (y-axis) is compared with the expected rawP-value
(x-axis, under null distribution) before a Bonferroni correction. (B) Graphical summary (Manhattan plot) presenting rawP-values for the association with
HSCR in 123 sporadic HSCR patients and 432 unaffected controls. The 2log10P (logistic regression analysis) is plotted against its physical position on
successive chromosomes. Gray line represents the threshold for GWAS significance after a Bonferroni correction.
doi:10.1371/journal.pone.0110292.g001
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this discrepancy between the Chinese and Korean studies might
be due to ethnic differences among Asian populations or different
inclusion ratios of the subgroups. However, among 41 NRG1 SNP
markers in our GWAS, several variants (for instance, rs7005606,
rs4733130, and rs6996957) also showed increased association
signals for HSCR (Table S2).
Five SNPs (rs12739262, rs12752277, rs2809867 on chromo-
some 1; rs36019094 on chromosome 5; rs35198051 on chromo-
some 11) showed genome-wide significance levels (Table S3).
Among these SNPs, PPP1R12B rs12739262 and SHANK2
rs35198051 (corrP=0.005 for both SNPs) are positioned at the
intron of the genes, whereas others are in intergenic or gene desert
regions. However, despite potential associations of SHANK2 with
the nervous system and neurodevelopmental diseases [15,16], no
observation of additionally significant associations of SHANK2
and PPP1R12B SNPs in our regional association results suggests
that these loci with genome-wide significance might be false-
positive findings. This study identified SLC6A20, RORA, and
ABCC9 as new potential susceptibility loci for HSCR. Four, nine,
and nineteen SNPs of SLC6A20, RORA, and ABCC9, respec-
tively, showed relatively robust association signals (adjP,0.001,
Table S4), suggesting that these genes might play a role in HSCR
susceptibility without the effects of the RET-CSGALNACT2-
RASGEF1A and NRG1 regions.
Although the functions of SLC6A20 and its gene product are
poorly understood, there are a few intriguing clues to the
relationship between SLC6A20 and HSCR. The human
SLC6A20 that is abundantly expressed in much of the gastroin-
testinal tract has been suggested as a target gene for a renal tubular
disorder of iminoaciduria [17,18]. Also, the combined mutations
in SLC6A20 and other genes have been observed to affect its
related human phenotypes [19], suggesting that genetic variations
Figure 2. Result of the analysis adjusted by RET-CSGALNACT2-RASGEF1A and NRG1 and top SNPs within the gene region. The adjP-value
(y-axis) after adjustment by rs2435357, rs1800860, and rs7078220 on RET-CSGALNACT2-RASGEF1A region and rs16879552 on NRG1 is plotted against
its physical position on successive chromosomes.
doi:10.1371/journal.pone.0110292.g002
Figure 3. Regional association and LD plots of SLC6A20, RORA, and ABCC9 SNPs for HSCR. Associations of SNPs across approximately (A) a
400 kb region around SLC6A20 on chromosome 3p21.3, (B) a 1,065 kb region around RORA on chromosome 15q22.2, and (C) a 500 kb region around
ABCC9 on chromosome 12p12.1, under analysis adjusted by RET-CSGALNACT2-RASGEF1A and NRG1, are shown. In the upper panel of each regional
association, strong associations are shown as large black circles; relatively weak associations are shown as small gray diamonds. In the lower panel,
LDs are indicated with LD coefficient (r2) between all pairs of biallelic loci.
doi:10.1371/journal.pone.0110292.g003
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of SLC6A20may also contribute to the development of the enteric
system when combined with other risk factors. On the other hand,
since LIMD1, a nearby gene of SCL6A20, has been shown to
affect cell migration that is essential during development [20], we
also analyzed LD between the seven SLC6A20 SNPs (adjP,0.01)
and two nearby genes (LIMD1 and SACM1L) that were most
likely to be in LD with SLC6A20. However, SLC6A20 showed no
LD with the nearby genes (Table S7), indicating that SLC6A20
may have roles without correlation to nearby genes, but may
interact with other regulators [21]. For other potential genes of
RORA and ABCC9, no literature clues related to HSCR or ENS
development could be found.
This study confirmed strong associations of SNPs on CSGAL-
NACT2 and RASGEF1A as nearby genes of RET and being in
tight LD with one another. However, the functions of CSGAL-
NACT2 and RASGEF1A are little understood. Only differential
expressions of these three genes have been previously observed in
human tissues: for instance, higher expression of RASGEF1A in
the colon but lower in the small intestine, when compared to RET
expressions [3]. Despite the insufficient sample size (in particular,
the low number of L-HSCR and TCA cases), our results also
identified other potential loci (Figure 4) that might contribute to
the phenotypes, such as length of aganglionosis, of the L-HSCR
and TCA subgroups. This evidence suggests that other regulators,
including distant-acting factors or chromosomal abnormalities,
may affect the development of ENS as well as HSCR [22,23].
Therefore, further studies, including replications in large cohorts
and deep sequencing of the RET-CSGALNACT2-RASGEF1A
region in HSCR patients, are needed.
Notably, there are additional observations from this study. First,
although the common RET rs2435357 within a conserved
enhancer-like sequence has been evaluated to be associated with
HSCR, possibly by affecting RET expression [3,24], this study has
found more significant associations at the top three intronic SNPs,
kgp4676284 (rs1864400, corrP=4.31610
213, Table S1),
kgp3302846 (rs741968, corrP=4.31610
213), and kgp11922846
(rs2742233, corrP=9.54610
213), which are in tight LD with each
other but not in LD with rs2435357 (Figure S4). However, in our
further in silico prediction analysis of potential branch point (BP)
sites for alternative splicing using the Human Splicing Finder
(http://www.umd.be/HSF/), these top three intronic SNPs did
not emerge as potential BP sites. Second, in the case of DSCAM as
a candidate gene in this study (Table S5), a most recent study has
reported that this gene may be a predisposing locus in HSCR [25].
Therefore, further functional evaluations of these new observa-
tions may also be required.
To date, the association between RET genetic variations and
HSCR has been identified in less than 30% of sporadic HSCR
cases [1]. To investigate the genetic heterogeneity for genomic
regions that showed the Bonferroni-corrected significances for
HSCR, SNPs across approximately a 196 kb region around the
RET-CSGALNACT2-RASGEF1A on chromosome 10 were
further analyzed. As a result, this genomic region showed a
relatively strong LD block (Figure S3). In addition, when a
multidimensional scaling (MDS) of the RET-CSGALNACT2-
RASGEF1A region for genetic heterogeneity was plotted, patients
were not divided into subgroups with specific genotypes, showing a
single cluster (Figure S5). Therefore, it is suggested that there may
be no genetic heterogeneity in these RET-CSGALNACT2-
RASGEF1A genomic regions showing significant associations
with HSCR.
Finally, several well-known HSCR- and/or enteric develop-
ment-related genes (EDNRB, GDNF, NRTN, SOX10, PHOX2B,
etc.) [1,2,26] showed no significant association signals in this study
(corrP.0.05, Table S8). Only, SNPs of EDNRB and ECE1
revealed nominal associations. The lack of associations in NRTN
and SOX10 is consistent with reports that have conflicting results
[27,28]. For EDN3 and ZFHX1B, the genetic diversity or the
complex phenotypes of patients with combined clinical features
might affect no replication of associations in this study [1,29,30].
This study found a small amount of inflation of test statistics as
the genomic control inflation factor is around 1.07. We applied the
linear mixed models (FaST-LMM) to correct for hidden related-
ness and found that inflation factor becomes 1.015. This indicates
that the linear mixed models successfully removed effects of hidden
relatedness as our inflation factor is close to 1. It was also found
that P-values of most of significant associations detected before
correcting for relatedness were consistent with P-values after
applying the linear mixed models.
In conclusion, our preliminary findings suggest that new
potential susceptibility loci, including SLC6A20, RORA, and
ABCC9 under adjusting the RET-CSGALNACT2-RASGEF1A
and NRG1 regions, may be related to the development of HSCR
or ENS-related disorders. However, there are several limitations of
this study, such as insufficient sample size and lack of replication.
In the case of statistical power of the sample size, it was calculated
as 58.5% due to the low numbers of subjects (in particular, L-
HSCR and TCA cases due to the rareness of the conditions).
Therefore, further replication study with independent samples and
functional evaluations of candidate genes are required. In order to
share data for further meta-analysis elsewhere, the summary
statistics (SNP ID, chromosome, position, allele variation, MAF,
OR with 95% CI, and P-value) for SNPs with association signals
(42,447 SNPs, rawP,0.05) were summarized in Table S9. In
addition, further observation on differential expressions of RET,
CSGALNACT2, and RASGEF1A among HSCR subgroups may
Figure 4. Manhattan plots of HSCR subgroup analysis. The strongest association RET-CSGALNACT2-RASGEF1A genomic region is observed at
chromosome 10. Other potential loci are indicated by arrows. P-value indicates the significance before a Bonferroni correction. (A) short-segment (S-
HSCR); (B) long-segment (L-HSCR); (C) total colonic aganglionosis (TCA).
doi:10.1371/journal.pone.0110292.g004
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help our understanding of HSCR pathogenesis and/or ENS
development.
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